1. Home
  2. CRBP

CRBP

Corbus Pharmaceuticals Holdings Inc.

Logo Corbus Pharmaceuticals Holdings Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Founded: 2009 Country:
United States
United States
Employees: N/A City: NORWOOD
Market Cap: 393.1M IPO Year: N/A
Target Price: $52.00 AVG Volume (30 days): 973.8K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -10.31 EPS Growth: N/A
52 Week Low/High: $3.03 - $49.87 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: